{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:28Z","timestamp":1707524488551},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,17]]},"DOI":"10.7759\/cureus.23266","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T19:25:48Z","timestamp":1647545148000},"source":"Crossref","is-referenced-by-count":0,"title":["Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy"],"prefix":"10.7759","author":[{"given":"Misbahuddin","family":"Khaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitesh","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Yapor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minu C","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolberto","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman SE","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, et al.. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011, 117:6287-96. 10.1182\/blood-2011-01-328484","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar M","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013, 37:1271-7. 10.1016\/j.leukres.2013.07.028","journal-title":"Leuk Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214561281","article-title":"A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib","volume":"22","author":"Lee CS","year":"2016","unstructured":"Lee CS, Rattu MA, Kim SS. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2016, 22:92-104. 10.1177\/1078155214561281","journal-title":"J Oncol Pharm Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2018.1555432","article-title":"Ibrutinib-induced cardiomyopathy","volume":"9","author":"Kyi HH","year":"2019","unstructured":"Kyi HH, Zayed Y, Al Hadidi S. Ibrutinib-induced cardiomyopathy. J Community Hosp Intern Med Perspect. 2019, 9:50-2. 10.1080\/20009666.2018.1555432","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5152\/eajm.2011.11","article-title":"Coronary vasospasm secondary to 5-fluorouracil and its management: case report","volume":"43","author":"Yildirim M","year":"2011","unstructured":"Yildirim M, Parlak C, Sezer C, Eryilmaz R, Kaya C, Yildiz M. Coronary vasospasm secondary to 5-fluorouracil and its management: case report. Eurasian J Med. 2011, 43:54-6. 10.5152\/eajm.2011.11","journal-title":"Eurasian J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2016-0081","article-title":"Cardio-oncology: cardiovascular complications of cancer therapy","volume":"13","author":"Henning RJ","year":"2017","unstructured":"Henning RJ, Harbison RD. Cardio-oncology: cardiovascular complications of cancer therapy. Future Cardiol. 2017, 13:379-96. 10.2217\/fca-2016-0081","journal-title":"Future Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-015-9502-y","article-title":"Chemotherapy-induced cardiomyopathy","volume":"20","author":"Higgins AY","year":"2015","unstructured":"Higgins AY, O'Halloran TD, Chang JD. Chemotherapy-induced cardiomyopathy. Heart Fail Rev. 2015, 20:721-30. 10.1007\/s10741-015-9502-y","journal-title":"Heart Fail Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-09992-5","article-title":"Precision cardio-oncology: a systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"13","author":"Brown SA","year":"2020","unstructured":"Brown SA, Ray JC, Herrmann J. Precision cardio-oncology: a systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors. J Cardiovasc Transl Res. 2020, 13:402-16. 10.1007\/s12265-020-09992-5","journal-title":"J Cardiovasc Transl Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al.. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015, 373:2425-37. 10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01102-1","article-title":"Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation","volume":"23","author":"Sestier M","year":"2021","unstructured":"Sestier M, Hillis C, Fraser G, Leong D. Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. Curr Oncol Rep. 2021, 23:113. 10.1007\/s11912-021-01102-1","journal-title":"Curr Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson T","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, et al.. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019, 134:1919-28. 10.1182\/blood.2019000840","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated\u00a0with ibrutinib","volume":"74","author":"Salem JE","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, et al.. Cardiovascular toxicities associated\u00a0with ibrutinib. J Am Coll Cardiol. 2019, 74:1667-78. 10.1016\/j.jacc.2019.07.056","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato AR","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, et al.. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016, 128:2199-205. 10.1182\/blood-2016-05-716977","journal-title":"Blood"},{"key":"ref14","article-title":"Goodman & Gilman's: the pharmacological basis of therapeutics","author":"Brunton LL","year":"2018","unstructured":"Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: the pharmacological basis of therapeutics. McGraw-Hill Education, New York, NY; 2018."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00334","article-title":"Ibrutinib-associated reversible cardiomyopathy","volume":"15","author":"Liang SH","year":"2019","unstructured":"Liang SH, Chiu CF, Bai LY. Ibrutinib-associated reversible cardiomyopathy. J Oncol Pract. 2019, 15:671-3. 10.1200\/JOP.19.00334","journal-title":"J Oncol Pract"},{"key":"ref16","article-title":"Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome","volume":"18","author":"Wasserstrum Y","year":"2016","unstructured":"Wasserstrum Y, Raanani P, Kornowski R, Iakobishvili Z. Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome. Isr Med Assoc J. 2016, 18:433-4.","journal-title":"Isr Med Assoc J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.719","article-title":"A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma","volume":"4","author":"Wallace N","year":"2016","unstructured":"Wallace N, Wong E, Cooper D, Chao H. A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep. 2016, 4:1120-1. 10.1002\/ccr3.719","journal-title":"Clin Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.03.016","article-title":"Biomarkers as predictors of cardiac toxicity from targeted cancer therapies","volume":"22","author":"Witteles RM","year":"2016","unstructured":"Witteles RM. Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. 2016, 22:459-64. 10.1016\/j.cardfail.2016.03.016","journal-title":"J Card Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90961-reversible-systolic-heart-failure-in-a-patient-on-ibrutinib-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:18Z","timestamp":1707507318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90961-reversible-systolic-heart-failure-in-a-patient-on-ibrutinib-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.23266","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}